Clinical trials: Cognitive Decline, Mild
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Alzheimer Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
- Trial name
- VIVA-MIND (NCT03919162)
- Testing
- PQ912
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Vivoryon Therapeutics N.V.
Mild Cognitive Impairment, Alzheimer Disease
Effect of Blueberry Supplementation on Alzheimer's Biomarkers
The purpose of this study is to study the effects of blueberries on neuronal, glial, and pathology blood biomarkers in Mild Cognitive Impairment (MCI) and to estimate sample size for future confirmatory studies.
- Trial name
- NCT05172128
- Testing
- lyophilized blueberry supplement
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Duke University
Alzheimer Dementia
A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.
Investigators are doing this research study to find out if methylphenidate (MPH) can help people with Mild Cognitive Impairment (MCI) or mild dementia likely due to Alzheimer's Disease (AD) and related disorders (ADRD).
- Trial name
- NCT03811847
- Testing
- Methylphenidate Extended Release Oral Capsule
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Mild Cognitive Impairment
Cognitive Ability Training in Seniors
This study investigates the beneficial effects of prefrontal brain stimulation (with transcranial direct current stimulation [tDCS]) during working memory training in seniors with subjective memory impairments.The…
- Trial name
- CATS (NCT02587338)
- Testing
- Verum tDCS
- Where
- Germany
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Wuerzburg University Hospital
Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology)
STIM+: PET Biomarker Education & Disclosure
When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging.
- Trial name
- STIM+ (NCT04818255)
- Testing
- PET Biomarker Disclosure
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Michigan
Alzheimer's Disease, Mild Cognitive Impairment
Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images
To Evaluate the Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]flutemetamol Positron Emission Tomography (PET) Images.
- Trial name
- NCT01672827
- Testing
- [18F]Flutemetamol
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Vascular Cognitive Impairment no Dementia
Memory and Antioxidants in Vascular Impairment Trial
This is a 24-week randomized, double-blind, placebo-controlled parallel group design study involving Vascular cognitive impairment-no dementia (VCIND) patients to evaluate the efficacy and safety of oral NAC supplementation…
- Trial name
- NCT03306979
- Testing
- N Acetylcysteine
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
This study consists of Part I and an optional Part II. The purpose of Part I is to compare the plasma pharmacokinetics of verubecestat (MK-8931) following administration of a single oral dose of 40 mg MK-8931 to participants with…
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- NCT02910739
- Testing
- MK-8931
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cognition
A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability
The purpose is to compare solifenacin and oxybutynin with an inactive tablet and assess any potential effects on mental ability.
- Trial name
- SENIOR (NCT01126424)
- Testing
- Solifenacin, Oxybutynin
- Where
- 3 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Mild Cognitive Impairment
ENgaging in Advance Care Planning Talks Group Visit Intervention for Cognitive Impairment
The Advance Care Planning Group Visit intervention is a new intervention that uses the strengths of group visits to promote advance care planning conversations and documentation.
- Trial name
- ENACT-aMCI (NCT03711396)
- Testing
- Advance Care Planning Group Visits
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Mild Cognitive Impairment (MCI), Mild Alzheimer Disease
Self-Administered Interactive Exercise Program (Tele-Exergame)
This longitudinal Phase I feasibility trial combines care-as-usual with a 6-week, single-arm exercise intervention using Tele-Exergame, an interactive, self-administered home-based exercise program aimed at improving…
- Conditions
- Mild Cognitive Impairment (MCI), Mild Alzheimer Disease, Memory Deficits
- Trial name
- NCT07072962
- Testing
- home-based self-administered interactive exercise
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Mild Cognitive Impairment
Metformin in Amnestic Mild Cognitive Impairment
Hyperinsulinemia and type 2 diabetes (T2D) are important potential risk factors for cognitive decline and Alzheimer's disease (AD).
- Trial name
- MCI (NCT00620191)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Columbia University
Mild Cognitive Impairment
Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.
Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain.
- Trial name
- NCT00040443
- Testing
- CX516
- Where
- 8 sites in United States
- Volunteers
- 175 people
- Sponsor
- RespireRx
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Spanish Language Homes
This study aims to develop, evaluate, and commercialize an in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT05159596
- Testing
- In-Home Technology System, Limited In-Home Technology
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
This 2-part, open-label study was designed to investigate the safety, tolerability, and efficacy of [18F]MK-6240, a Positron Emission Tomography (PET) imaging agent, for the quantification of neurofibrillary tangle (NFT)…
- Trial name
- NCT02562989
- Testing
- [18F]MK-6240, ~185 MBq, [18F]MK-6240, ~160 MBq
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment, Ischemic Stroke
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
The purpose of this study is: to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke to evaluate safety of MMH-MAP in the treatment of mild…
- Trial name
- NCT03815292
- Testing
- MMH-MAP
- Where
- 28 sites in Russia
- Volunteers
- 276 people
- Sponsor
- Materia Medica Holding
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
This study consists of two parts, Part 1 and Part 2. Part 1 assesses the efficacy and safety of verubecestat (MK-8931) compared with placebo administered for 104 weeks in the treatment of amnestic mild cognitive impairment (aMCI)…
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- APECS (NCT01953601)
- Testing
- Verubecestat 12 mg (Parts 1 and 2), Verubecestat 40 mg (Parts 1 and 2)
- Volunteers
- 1,454 people
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment
Plasticity Using Stimulation and Habit: A Pilot Open-label rTMS Study for MCI
The goal of this pilot study is to determine whether a high-dose form of non-invasive brain stimulation is a promising and safe treatment for Mild Cognitive Impairment (MCI).
- Trial name
- PUSH-Pilot (NCT04503096)
- Testing
- High-dose accelerated rTMS
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medical University of South Carolina
Cognitive Impairment, Depression
Problem Adaptation Therapy for Mild Cognitive Impairment and Depression
The present collaborative R01 study, between Cornell and Johns Hopkins, aims to compare Problem Adaptation Therapy for Mild Cognitively Impaired Older Adults (PATH-MCI) vs.
- Trial name
- PATH-MCI (NCT03043573)
- Testing
- PATH-MCI, Supportive Therapy
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Weill Medical College of Cornell University